therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2023-4-4-6-13therapeutic-392Research ArticleОБЗОРЫREVIEWSФармакотерапия гипертрофической кардиомиопатииPharmacotherapy for hypertrophic cardiomyopathyhttps://orcid.org/0000-0003-3611-1186ИгнатенкоГ. А.IgnatenkoG. A.

Игнатенко Григорий Анатольевич - д.м.н., ректор, заведующий кафедрой пропедевтики внутренних болезней.

Донецк, ДНР

Grigory A. Ignatenko - Dr. Sci. (Med.), Donetsk State Medical University n. a. M. Gorky.

Donetsk, Donetsk People’s Republic

gai-1959@mail.ruhttps://orcid.org/0000-0003-3984-8482ТарадинГ. Г.TaradinG. G.

Тарадин Геннадий Геннадьевич - к.м.н., заведующий кафедрой терапии ФИПО им. проф. А.И. Дядыка.

Донецк, ДНР

Gennadiy G. Taradin - Cand. Sci. (Med.), Donetsk State Medical University n. a. M. Gorky.

Donetsk, Donetsk People’s Republic

taradin@inbox.ruhttps://orcid.org/0009-0005-4560-2632КононенкоЛ. В.KononenkoL. V.

Кононенко Людмила Викторовна - ассистент кафедры терапии ФИПО им. проф. А.И. Дядыка.

Донецк, ДНР

Ludmila V. Kononenko - Donetsk State Medical University n. a. M. Gorky.

Donetsk, Donetsk People’s Republic

liudmilavikkononenko@yandex.ruФГБОУ ВО «Донецкий государственный медицинский университет им. М. Горького» Минздрава РоссииРоссияDonetsk State Medical University n. a. M. GorkyRussian Federation20232011202344613Copyright © Игнатенко Г.А., Тарадин Г.Г., Кононенко Л.В., 20232023Игнатенко Г.А., Тарадин Г.Г., Кононенко Л.В.Ignatenko G.A., Taradin G.G., Kononenko L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/392

Представленный обзор посвящён современным подходам лекарственной терапии гипертрофической кардиомиопатии. Затронуты общие вопросы лечения, включая модификацию образа жизни, поддержание адекватной гидратации и избежание ситуаций, способствующих усилению обструкции. Описана роль традиционно используемых b-адреноблокаторов и недигидропиридиновых блокаторов кальциевых каналов в лечении заболевания. Приведены данные по применению дизопирамида, лечение которым позволяет уменьшить градиент обструкции, выраженность клинических проявлений заболевания и улучшить диастолическую функцию. Особое внимание уделено новому классу препаратов — ингибиторам кардиального миозина, а именно мавакамтену и афикамтену. Сообщаются результаты рандомизированных клинических исследований, посвящённых оценке эффективности этих препаратов. Представлен современный взгляд на место в терапии гипертрофической кардиомиопатии пергексилина, триметазидина, ранолазина, элеклазина, блокаторов рецепторов ангиотензина II, а также комбинации сакубитрила и валсартана.

The presented review concerns modern approaches to drug therapy for hypertrophic cardiomyopathy. General issues of the treatment are touched upon, including lifestyle modification, maintaining adequate hydration and avoiding situations that increase obstruction. The role of traditionally used b-blockers and non-dihydropyridine calcium channel blockers in the treatment of the disease is described. Data on the use of disopyramide are presented, the treatment of which allows reducing the obstruction gradient, ameliorating clinical manifestations and improving diastolic function. Special attention is paid to a new class of drugs — cardiac myosin inhibitors: mavacamten and aficamten. The results of randomized clinical trials regarding to evaluating the efficacy of these drugs are reported. The review presents a modern view of the place of perhexiline, trimetazidine, ranolazine, eleclazine, angiotensin II receptor blockers, combination of sacubitril and valsartan in the therapy of hypertrophic cardiomyopathy.

гипертрофическая кардиомиопатиятерапияфармакотерапиялечениемавакамтенафикамтенhypertrophic cardiomyopathytherapypharmacotherapytreatmentmavacamtenaficamtenReferencesMaron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi: 10.1016/j.jacc.2020.08.045Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi: 10.1016/j.jacc.2020.08.045Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л. и др. Гипертрофическая кардиомиопатия. Клинические рекомендации. 2020. Российский кардиологический журнал. 2021;26(5):4541. doi: 10.15829/1560-4071-2021-4541Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л. и др. Гипертрофическая кардиомиопатия. Клинические рекомендации. 2020. Российский кардиологический журнал. 2021;26(5):4541. doi: 10.15829/1560-4071-2021-4541Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35-42. doi: 10.15829/1560-4071-2014-5-35-42Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35-42. doi: 10.15829/1560-4071-2014-5-35-42Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ, et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol. 2016;68(15):1651-1660. doi: 10.1016/j.jacc.2016.07.751Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ, et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol. 2016;68(15):1651-1660. doi: 10.1016/j.jacc.2016.07.751Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: new concepts and therapies. Annu Rev Med. 2022;73:363-375. doi: 10.1146/annurev-med-042220-021539Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: new concepts and therapies. Annu Rev Med. 2022;73:363-375. doi: 10.1146/annurev-med-042220-021539Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021Гудкова А.Я., Стрельцова А.А., Костарева А.А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению. Терапевтический архив. 2019;91(9):129–136. doi: 10.26442/00403660.2019.09.000137Гудкова А.Я., Стрельцова А.А., Костарева А.А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению. Терапевтический архив. 2019;91(9):129–136. doi: 10.26442/00403660.2019.09.000137Packard E, de Feria A, Peshin S, Reza N, Owens AT. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy. Cardiol Ther. 2022;11(4):491-507. doi: 10.1007/s40119-022-00283-5Packard E, de Feria A, Peshin S, Reza N, Owens AT. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy. Cardiol Ther. 2022;11(4):491-507. doi: 10.1007/s40119-022-00283-5Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B, et al. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep. 2021;18(4):169-179. doi: 10.1007/s11897-021-00523-0Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B, et al. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep. 2021;18(4):169-179. doi: 10.1007/s11897-021-00523-0Spoladore R, Fragasso G, Pannone L, Slavich M, Margonato A. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy. Expert Opin Pharmacother. 2020;21(2):233-242. doi: 10.1080/14656566.2019.1702023Spoladore R, Fragasso G, Pannone L, Slavich M, Margonato A. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy. Expert Opin Pharmacother. 2020;21(2):233-242. doi: 10.1080/14656566.2019.1702023Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Hypertrophic obstructive cardiomyopathy. Dtsch Arztebl Int. 2019;116(4):47-53. doi: 10.3238/arztebl.2019.0047Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Hypertrophic obstructive cardiomyopathy. Dtsch Arztebl Int. 2019;116(4):47-53. doi: 10.3238/arztebl.2019.0047Sanchez-Nadales A, Anampa-Guzmán A, Khan A. Disopyramide for hypertrophic cardiomyopathy. Cureus. 2019;11(4):e4526. doi: 10.7759/cureus.4526Sanchez-Nadales A, Anampa-Guzmán A, Khan A. Disopyramide for hypertrophic cardiomyopathy. Cureus. 2019;11(4):e4526. doi: 10.7759/cureus.4526Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-8. doi: 10.1016/j.jacc.2005.01.012Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-8. doi: 10.1016/j.jacc.2005.01.012Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141(10):828-842. doi: 10.1161/CIRCULATIONAHA.119.042339Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141(10):828-842. doi: 10.1161/CIRCULATIONAHA.119.042339Autore C, Francia P, Tini G, Musumeci B. Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl B):B12-B15. doi: 10.1093/eurheartjsupp/suad060Autore C, Francia P, Tini G, Musumeci B. Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl B):B12-B15. doi: 10.1093/eurheartjsupp/suad060Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228-240. doi: 10.1002/ejhf.1715Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228-240. doi: 10.1002/ejhf.1715Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-XOlivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-XWheeler MT, Olivotto I, Elliott PM, Saberi S, Owens AT, Maurer MS, et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the explorer-hcm randomized trial. JAMA Cardiol. 2023;8(3):240-247. doi: 10.1001/jamacardio.2022.5099Wheeler MT, Olivotto I, Elliott PM, Saberi S, Owens AT, Maurer MS, et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the explorer-hcm randomized trial. JAMA Cardiol. 2023;8(3):240-247. doi: 10.1001/jamacardio.2022.5099Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064Dalo JD, Weisman ND, White CM. Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. Ann Pharmacother. 2023;57(4):489-502. doi: 10.1177/10600280221117812Dalo JD, Weisman ND, White CM. Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. Ann Pharmacother. 2023;57(4):489-502. doi: 10.1177/10600280221117812Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al. Discovery of aficamten (ck-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al. Discovery of aficamten (ck-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562-1569. doi: 10.1161/CIRCULATIONAHA.109.934059Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562-1569. doi: 10.1161/CIRCULATIONAHA.109.934059Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4(3):230-235. doi: 10.1001/jamacardio.2018.4847Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4(3):230-235. doi: 10.1001/jamacardio.2018.4847Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815-1817. doi: 10.1016/j.jacc.2016.07.758Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815-1817. doi: 10.1016/j.jacc.2016.07.758Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: The RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018;11(1):e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: The RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018;11(1):e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889-912. doi: 10.1007/s40265-022-01728-wPalandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889-912. doi: 10.1007/s40265-022-01728-wOlivotto I, Hellawell JL, Farzaneh-Far R, Blair C, Coppini R, Myers J, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) Trial. Circ Heart Fail. 2016;9(3):e002764. doi: 10.1161/CIRCHEARTFAILURE.115.002764Olivotto I, Hellawell JL, Farzaneh-Far R, Blair C, Coppini R, Myers J, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) Trial. Circ Heart Fail. 2016;9(3):e002764. doi: 10.1161/CIRCHEARTFAILURE.115.002764Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010;120(10):3520-3529. doi: 10.1172/JCI42028Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010;120(10):3520-3529. doi: 10.1172/JCI42028Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-131. doi: 10.1016/S2213-8587(14)70241-4Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-131. doi: 10.1016/S2213-8587(14)70241-4Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480-487. doi: 10.1016/j.jchf.2013.09.001Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480-487. doi: 10.1016/j.jchf.2013.09.001Abdelazeem B, Abbas KS, Ahmad S, Raslan H, Labieb F, Savarapu P. The effect of angiotensin II receptor blockers in patients with hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. 2022;23(4):141. doi: 10.31083/j.rcm2304141Abdelazeem B, Abbas KS, Ahmad S, Raslan H, Labieb F, Savarapu P. The effect of angiotensin II receptor blockers in patients with hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. 2022;23(4):141. doi: 10.31083/j.rcm2304141Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al; PARALLAX Investigators and Committee members. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919-1929. doi: 10.1001/jama.2021.18463Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al; PARALLAX Investigators and Committee members. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919-1929. doi: 10.1001/jama.2021.18463Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2020;43(5):430-440. doi: 10.1002/clc.23346Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2020;43(5):430-440. doi: 10.1002/clc.23346

The authors declare that there are no conflicts of interest present.